Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Aug 28;21(17):6240.
doi: 10.3390/ijms21176240.

CRISPR-Cas9 DNA Base-Editing and Prime-Editing

Affiliations
Review

CRISPR-Cas9 DNA Base-Editing and Prime-Editing

Ariel Kantor et al. Int J Mol Sci. .

Abstract

Many genetic diseases and undesirable traits are due to base-pair alterations in genomic DNA. Base-editing, the newest evolution of clustered regularly interspaced short palindromic repeats (CRISPR)-Cas-based technologies, can directly install point-mutations in cellular DNA without inducing a double-strand DNA break (DSB). Two classes of DNA base-editors have been described thus far, cytosine base-editors (CBEs) and adenine base-editors (ABEs). Recently, prime-editing (PE) has further expanded the CRISPR-base-edit toolkit to all twelve possible transition and transversion mutations, as well as small insertion or deletion mutations. Safe and efficient delivery of editing systems to target cells is one of the most paramount and challenging components for the therapeutic success of BEs. Due to its broad tropism, well-studied serotypes, and reduced immunogenicity, adeno-associated vector (AAV) has emerged as the leading platform for viral delivery of genome editing agents, including DNA-base-editors. In this review, we describe the development of various base-editors, assess their technical advantages and limitations, and discuss their therapeutic potential to treat debilitating human diseases.

Keywords: CRISPR/Cas9; adeno-associated vector; base-editing; gene therapy; genome engineering; prime-editing.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

Figures

Figure 1
Figure 1
CRISPR DNA Base-Editing Tools. (A) DNA Base-editing. DNA base-editors encompass two key components: a Cas enzyme for programmable DNA binding and a single-stranded DNA modifying enzyme for targeted nucleotide alteration. Two classes of DNA base-editors have been described: cytosine base-editors and adenine base-editors. Cytosine deamination generates uracil, which base pairs as thymidine in DNA. Fusion of uracil DNA glycosylase inhibitor (UGI) inhibits the activity of uracil N-glycosylate (UNG), thus increasing the editing efficiency of cytosine base-editing in human cells. Adenosine deamination generates inosine, which has the same base pairing preferences as a guanosine in DNA. Collectively, cytosine and adenine base-editing can install all four transition mutations (C→T, T→C, A→G, and G→A). (B) Prime-editing. Prime-editors use an engineered reverse transcriptase fused to Cas9 nickase and a prime-editing guide RNA (pegRNA). The pegRNA contains the sequence complimentary to the target sites that directs nCas9 to its target sequence as well as an additional sequence spelling the desired sequence changes. Prime-editors expand the scope of DNA editing to not all transition and transversion mutations, as well as small insertion and deletion mutations.

References

    1. Doudna J.A., Charpentier E. Genome editing. The new frontier of genome engineering with CRISPR-Cas9. Science. 2014;346:1258096. doi: 10.1126/science.1258096. - DOI - PubMed
    1. Gallagher D.N., Haber J.E. Repair of a Site-Specific DNA Cleavage: Old-School Lessons for Cas9-Mediated Gene Editing. ACS Chem. Biol. 2018;13:397–405. doi: 10.1021/acschembio.7b00760. - DOI - PMC - PubMed
    1. Rouet P., Smih F., Jasin M. Introduction of double-strand breaks into the genome of mouse cells by expression of a rare-cutting endonuclease. Mol. Cell. Biol. 1994;14:8096–8106. doi: 10.1128/MCB.14.12.8096. - DOI - PMC - PubMed
    1. Sander J.D., Joung J.K. CRISPR-Cas systems for editing, regulating and targeting genomes. Nat. Biotechnol. 2014;32:347–355. doi: 10.1038/nbt.2842. - DOI - PMC - PubMed
    1. Mao Z., Bozzella M., Seluanov A., Gorbunova V. Comparison of nonhomologous end joining and homologous recombination in human cells. DNA Repair (Amst) 2008;7:1765–1771. doi: 10.1016/j.dnarep.2008.06.018. - DOI - PMC - PubMed

Substances